ACAM 2000

Drug Profile

ACAM 2000

Alternative Names: ACAM 1000; ACAM2000; Smallpox (vaccinia) live vaccine - Sanofi Pasteur Biologics; Smallpox vaccine - Sanofi Pasteur Biologics

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur Biologics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Smallpox

Most Recent Events

  • 06 Oct 2017 Emergent BioSolutions acquires ACAM2000 from Sanofi
  • 25 Sep 2017 ACAM 2000 is approved and will be made available should a small pox outbreak arise
  • 17 Jul 2017 Emergent BioSolutions to acquire ACAM 2000 from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top